◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › PEN

Penumbra Inc (PEN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-07-25

Penumbra Inc (PEN) operates in the MEDICAL DEVICES industry and is headquartered in Alameda, United States with about 4,700 employees. Its market capitalization is roughly $13 billion. In the fiscal year ended 2025-12-31, PEN reported $1.4B in revenue and $178M in net income.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.

Interactive charts & full statements → Open the PEN valuation workbench →

PEN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$1.5B	$1.4B	$1.2B	$1.1B	$847M	$748M	$560M	$547M	$445M	$334M	$263M	$186M	$126M	$89M	$73M
Gross Profit	$980M	$942M	$755M	$683M	$535M	$475M	$338M	$372M	$293M	$217M	$171M	$124M	$83M	$58M	$49M
Gross Margin %	67.4%	67.1%	63.2%	64.5%	63.2%	63.6%	60.3%	68.0%	65.8%	65.1%	64.9%	66.7%	66.0%	65.1%	66.9%
Operating Income (EBIT)	$187M	$189M	$9M	$74M	$6M	($8M)	($39M)	$48M	($1M)	$1M	($1M)	$4M	$3M	($1M)	$3M
Operating Margin %	12.9%	13.5%	0.8%	7.0%	0.7%	-1.0%	-7.0%	8.7%	-0.2%	0.4%	-0.5%	2.2%	2.4%	-1.3%	4.7%
Net Income	$171M	$178M	$14M	$91M	($2M)	$3M	($19M)	$48M	$7M	$5M	$15M	$2M	$2M	$4M	$2M
Net Margin %	11.8%	12.7%	1.2%	8.6%	-0.2%	0.4%	-3.4%	8.8%	1.5%	1.4%	5.6%	1.3%	1.8%	4.6%	2.7%
EBITDA	$221M	$223M	$46M	$109M	$30M	$9M	($26M)	$56M	$36M	$5M	$1M	$6M	$4M	$0M	$3M
Earnings Per Share (EPS)	$4.35	$4.52	$0.36	$2.32	$-0.05	$0.07	$-0.54	$1.34	$0.18	$0.13	$0.44	$0.17	$0.09	$0.17	$0.08
Shares Outstanding (M)	40M	39M	39M	39M	38M	38M	36M	36M	36M	35M	33M	14M	25M	25M	25M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PEN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$375M	$385M	$355M	$339M	$324M	$316M	$301M	$299M
Gross Profit	$253M	$262M	$240M	$224M	$216M	$211M	$200M	$163M
Gross Margin %	67.6%	68.0%	67.8%	66.0%	66.6%	66.8%	66.5%	54.4%
Operating Income (EBIT)	$38M	$59M	$49M	$41M	$40M	$43M	$35M	($81M)
Operating Margin %	10.2%	15.4%	13.8%	12.0%	12.4%	13.6%	11.8%	-27.0%
Net Income	$33M	$47M	$46M	$45M	$39M	$34M	$30M	($60M)
Net Margin %	8.7%	12.3%	12.9%	13.3%	12.1%	10.7%	9.8%	-20.1%
EBITDA	$47M	$68M	$55M	$51M	$49M	$49M	$44M	($70M)
Earnings Per Share (EPS)	$0.82	$1.20	$1.17	$1.15	$1.00	$0.86	$0.75	$-1.55
Shares Outstanding (M)	40M	39M	39M	39M	39M	39M	39M	39M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PEN Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	$277M	$239M	$168M	$97M	($56M)	$10M	($33M)	$27M	$29M	$13M	($13M)	($22M)	($6M)	($3M)
Capital Expenditures (CapEx)	$64M	$64M	$21M	$15M	$19M	$21M	$25M	$22M	$10M	$15M	$14M	$5M	$4M	$1M
Free Cash Flow (FCF)	$213M	$175M	$147M	$82M	($75M)	($12M)	($58M)	$5M	$19M	($2M)	($26M)	($28M)	($10M)	($4M)
FCF Margin %	14.6%	12.5%	12.3%	7.8%	-8.8%	-1.6%	-10.3%	0.8%	4.3%	-0.7%	-10.0%	-14.9%	-8.2%	-4.7%
Dividends Paid	—	—	—	—	$8M	$16M	$10M	$19M	—	$0M	$0M	$0M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PEN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$87M	$86M	$58M	$45M	$49M	$51M	$56M	$23M
Capital Expenditures (CapEx)	$14M	$18M	$16M	$16M	$13M	$5M	$5M	$5M
Free Cash Flow (FCF)	$73M	$68M	$42M	$29M	$36M	$46M	$51M	$18M
FCF Margin %	19.6%	17.7%	11.8%	8.6%	10.9%	14.5%	17.0%	6.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PEN Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$1.9B	$1.8B	$1.5B	$1.6B	$1.4B	$1.2B	$823M	$666M	$515M	$477M	$308M	$264M	$121M	$71M
Cash & Cash Equivalents	$241M	$187M	$324M	$167M	$70M	$59M	$70M	$73M	$68M	$51M	$13M	$20M	$3M	$4M
Total Liabilities	$425M	$399M	$382M	$377M	$372M	$290M	$185M	$180M	$93M	$76M	$42M	$31M	$134M	$79M
Total Debt (Short + Long-Term)	$17M	$16M	$15M	$13M	$12M	$10M	$6M	$8M	$0M	$0M	$0M	$0M	$0M	$6M
Total Shareholders' Equity	$1.5B	$1.4B	$1.2B	$1.2B	$999M	$954M	$641M	$486M	$422M	$400M	$267M	$233M	($12M)	($8M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PEN viewer.

Other Companies in MEDICAL DEVICES

PHG · Koninklijke Philips NV ADR — $25 billion
SNN · Smith & Nephew SNATS Inc — $13 billion

← PEGA All stocks PENG →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.